Kit and method for constructing heart organoid from pluripotent stem cells

By using multifunctional stem cells and specific induction medium components, the heart organoids with autonomous pulsation were successfully cultivated, which solved the problem that the existing technology could not cultivate 3D cardiac organoids, and achieved efficient and repeatable construction and electrical engineering of cardiac organoids Physiologically stable, suitable for drug development and heart development research.

WO2024234457A1PCT designated stage expired Publication Date: 2024-11-21WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/104969
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2023-06-30
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The prior art cannot successfully cultivate cardiac organoids with 3D structures, single-layer cardiomyocytes cannot simulate the development process of the human heart, and are difficult to use for drug response prediction, and there is a lack of commercially available cardiac organoid kits on the market.

Method used

Provide a kit for constructing cardiac organoids from multifunctional stem cells, including basal induction medium and induction medium components, through specific additives (such as CHIR99021, Y-27632, IWR-1, TA-01, TA-02 ) Induce multifunctional stem cells to form cardiac organoids, the steps include multiple replacement of different concentrations of induction medium until the cardiac organoids show autonomous pulsation and cardiac muscle cell gene expression.

Benefits of technology

It realizes standardized and repeatable batch manufacturing of cardiac organoids with autonomous pulsation in the laboratory, filling the market gap, and is suitable for drug development, safety evaluation and cardiac development research. The built cardiac organoids are electrophysiologically stable and have high capability. Repeatability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2023104969-FTAPPB-I100001
    Figure PCTCN2023104969-FTAPPB-I100001
  • Figure 00000009_0000
    Figure 00000009_0000
  • Figure 00000010_0000
    Figure 00000010_0000
Patent Text Reader

Abstract

A kit for constructing a heart organoid from pluripotent stem cells, and a method for constructing a heart organoid by using the kit. The objective of standardized and repeatable mass production of heart organoids in a laboratory is achieved; the construction of an autonomously beating heart organoid can be achieved within 15 days; and the constructed heart organoid is electrophysiologically stable, has high repeatability, and is suitable for application including drug development, safety evaluation, heart development process research, etc. Moreover, the kit is also suitable for the culture of monolayer myocardial cells, and provides more choices for the culture of monolayer myocardial cells.
Need to check novelty before this filing date? Find Prior Art

Description

A kit and method for constructing cardiac organoids from pluripotent stem cells Technical Field

[0001] The present invention belongs to the field of organoid culture, and specifically relates to a kit and method for constructing cardiac organoids from pluripotent stem cells. Background Art

[0002] In recent years, organoid technology has developed rapidly and is regarded as one of the most groundbreaking cutting-edge scientific technologies in the field of life sciences, and is also a current research hotspot. As a 3D cell culture cultured from stem cells in vitro, organoids exhibit remarkable self-organizing characteristics and are highly homologous to the original tissue in terms of morphology, structure, gene expression, etc., breaking the limitations of current traditional in vivo and in vitro models, and providing a new research idea for the development of medicine and new drugs. So far, researchers have successfully cultured organoids such as brain, intestine, stomach, liver, and pancreas in vitro, but progress in the field of cardiac organoids has been slow. Currently, companies such as Stem cell Technology have launched organoid kits such as liver, pancreas, kidney and brain, which can solve the problem of organoid culture in one stop, but there is still a gap in the market for commercially available cardiac organoid kits.

[0003] Existing research reports on culture kits related to cardiac organoids are limited to the culture and differentiation of cardiomyocytes. For example, Chinese patent application publication number CN105473708A discloses an aqueous culture medium base composition containing a thyroid hormone-like compound, a mixture thereof, and a carnitine compound, which can produce adult-like cardiomyocytes from stem cells that differentiate into (fetal) cardiomyocytes. Another example is Chinese patent application publication number CN106244526A, which discloses a cardiomyocyte differentiation kit and a cardiomyocyte culture method, including a cardiomyocyte differentiation base culture medium: a sugar-containing 1640 culture medium, and cardiomyocyte differentiation additives such as B27 and BMP4. However, this kit can only be used for the directed differentiation of stem cells to form a monolayer of cardiomyocytes, but cannot culture cardiac organoids with a 3D structure. Compared to cardiac organoids, monolayer cardiomyocytes lack a 3D structure and the organoid's own microenvironment, making them unable to simulate the development process of the human heart and difficult to use to accurately predict the response of drugs in the human environment.

[0004] Therefore, in order to fill the gap in existing technologies in cardiac organoid culture, providing a culture kit and method for constructing cardiac organoids with high success rate and reproducibility is of great significance for promoting the development of cardiac therapeutic drugs, safety evaluation and cardiac development research.

[0005] Summary of the Invention

[0006] The purpose of the present invention is to provide a kit and method for constructing cardiac organoids from pluripotent stem cells.

[0007] The present invention provides a kit for constructing cardiac organoids from pluripotent stem cells, comprising a basal induction medium component, wherein the basal induction medium component is composed of the following raw materials in parts by volume:

[0008] DMEM medium 50 parts, MEM vitamin solution 0.05 parts, yeast powder ultrafiltrate 0.1 parts, vitamin E 5 parts, synthetic cholesterol 0.1 parts, yeast extract 3 parts, bovine serum albumin 5 parts, soybean hydrolyzate 5 parts;

[0009] The vitamin E is a vitamin E solution with a concentration of 0.96 g / mL.

[0010] Furthermore, the above-mentioned kit includes induction medium component A; the induction medium component A includes the basic induction medium component, and also includes additives with the following final concentrations added to the basic induction medium component: CHIR99021 15-25 μM, Y-27632 15-25 μM.

[0011] Furthermore, the induction medium component A is composed of the basic induction medium component and the additive; the final concentration of the additive is: CHIR99021 20 μM, Y-27632 20 μM.

[0012] Furthermore, the above kit includes an induction medium component B, which includes the basic induction medium component and an additive added to the basic induction medium component with the following final concentration: CHIR99021 5-15 μM.

[0013] Furthermore, the above-mentioned induction medium component B consists of the basic induction medium component and the additive; the final concentration of the additive is: CHIR99021 10 μM.

[0014] Furthermore, the above-mentioned kit includes an induction medium component C, which includes the basic induction medium component and also includes additives with the following final concentrations added to the basic induction medium component: IWR-1 15-25 μM, TA-01 10-20 μM, and TA-02 10-20 μM.

[0015] Furthermore, the above-mentioned induction medium component C is composed of the basic induction medium component and the additives; the final concentrations of the additives are: IWR-1 20 μM, TA-01 15 μM, and TA-02 15 μM.

[0016] Furthermore, the above-mentioned kit includes a basal induction medium component, an induction medium component A, an induction medium component B and an induction medium component C;

[0017] The basal induction medium is composed of the following raw materials: DMEM medium 50 mL, MEM vitamin solution 50 μL, yeast powder ultrafiltrate 100 μL, vitamin E 5 mL, synthetic cholesterol 100 μL, yeast extract 3 mL, bovine serum albumin 5 mL, and soybean hydrolyzate 5 mL;

[0018] The induction medium component A is composed of the following raw materials: the raw materials of the basic induction medium; and CHIR99021 with a final concentration of 20 μM and Y-27632 with a final concentration of 20 μM added to the raw material mixture of the basic induction medium;

[0019] The induction medium component B is composed of the following raw materials: the raw materials of the basic induction medium; and CHIR99021 with a final concentration of 10 μM added to the raw material mixture of the basic induction medium;

[0020] The induction medium component C is composed of the following raw materials: the raw materials of the basal induction medium; and IWR-1 with a final concentration of 20 μM, TA-01 with a final concentration of 15 μM, and TA-02 with a final concentration of 15 μM added to the raw material mixture of the aforementioned basal induction medium.

[0021] The present invention also provides a method for constructing cardiac organoids from pluripotent stem cells, comprising the step of inducing and culturing the pluripotent stem cells using the above-mentioned kit.

[0022] Furthermore, the above method comprises the following steps:

[0023] (1) Cultivating human pluripotent stem cells in induction medium A for 1 day;

[0024] (2) Change to induction medium B and culture for 1 day;

[0025] (3) Change to basal induction medium and culture for 1 day;

[0026] (4) Change to induction medium C for 3 days, and change to fresh induction medium C every day;

[0027] (5) Continue culturing by replacing the basal induction medium with fresh basal induction medium every 2 days until the spontaneous beating of the cardiac organoids and / or cardiac muscle cell gene expression occur.

[0028] Beneficial effects of the present invention: The present invention provides a kit for constructing cardiac organoids from pluripotent stem cells, achieving standardized, reproducible, and batch-produced cardiac organoids in the laboratory, filling a current market gap. The kit and method of the present invention can construct autonomously beating cardiac organoids within 15 days. The constructed cardiac organoids are electrophysiologically stable and highly reproducible, making them suitable for applications including drug development, safety evaluation, and research on cardiac development. Furthermore, the kit of the present invention is also suitable for culturing cardiomyocyte monolayers, providing more options for monolayer cardiomyocyte culture.

[0029] Obviously, based on the above contents of the present invention, according to common technical knowledge and customary means in this field, without departing from the above basic technical ideas of the present invention, other various forms of modifications, replacements or changes can be made.

[0030] The following further describes the above content of the present invention in detail through specific embodiments in the form of examples. However, this should not be construed as limiting the scope of the above subject matter of the present invention to the following examples. All technologies implemented based on the above content of the present invention fall within the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] FIG1 is a schematic diagram of the culture process for constructing cardiac organoids according to the present invention.

[0032] FIG2 is an immunofluorescence characterization of cardiomyocytes differentiated from hESCs (MLC2A, Troponin T (cTnT), α-Actinin and NKX2-5).

[0033] Figure 3 shows the immunofluorescence identification (DAPI, NKX2-5, Troponin T and MLC2A) of cardiac organoid sections differentiated from hESCs.

[0034] FIG4 shows HE staining identification of cardiac organoids differentiated from hESCs.

[0035] FIG5 shows the spontaneous beating statistics and electrophysiological signal analysis records of cardiac organoids differentiated and cultured from hESCs.

[0036] Figure 6 is (a) an optical microscope image (4X) of the heart organoids cultured in Example 2 of the present invention; (b) an optical microscope image of the heart organoids cultured in Comparative Example 1; and (c) an optical microscope image of the heart organoids cultured in Comparative Example 2. DETAILED DESCRIPTION

[0037] Unless otherwise specified, the raw materials and equipment used in the present invention are all known products and are obtained by purchasing commercially available products.

[0038] The human pluripotent stem cells (hESCs, hIPSCs) used in the present invention are pre-cultured with mTeSR before being cultured in the culture medium of the kit of the present invention. TM 1 medium for 3 days.

[0039] Example 1. Composition of the kit of the present invention

[0040] The raw material components provided in the kit of this embodiment are sufficient to prepare the following raw material components: basal induction medium, induction medium A, induction medium B, and induction medium C:

[0041] DMEM medium (Gibco, C11995500BT), MEM vitamin solution (x1000), Gibco, 11120052), yeast ultrafiltrate (Yeastolate Ultrafiltrate (x500), Gibco 292804), vitamin E (Sigma-Aldrich, T3376), synthetic cholesterol (Synthechol (cholesterol) (x500), Merck, S5442), yeast extract (Sigma-Aldrich, Y1625), bovine serum albumin (Solarbio, A8010), and soybean hydrolysate (Sigma-Aldrich, 58903C).

[0042] The composition of each culture medium is as follows:

[0043] 1. Basal induction medium: Use DMEM medium as the basal medium, add MEM vitamin solution with a volume of 1 / 1000 of the volume of DMEM medium, and yeast powder ultrafiltrate with a volume of 1 / 500 of the volume of DMEM medium (final concentration 10 μL / mL), mix well, and then add additives according to the concentrations in the table below:

[0044] 2. Induction medium A:

[0045] Basal induction medium, CHIR99021 at a final concentration of 20 μM, and Y-27632 at a final concentration of 20 μM.

[0046] 3. Induction medium B:

[0047] Basal induction medium, CHIR99021 at a final concentration of 10 μM.

[0048] 4. Induction medium C:

[0049] Basal induction medium, final concentrations of 20 μM IWR-1, 15 μM TA-01, and 15 μM TA-02.

[0050] Example 2: Construction and culture of cardiac organoids

[0051] The culture process diagram is shown in Figure 1. The specific steps are as follows:

[0052] Day (0) Human pluripotent stem cells (hESCs, hIPSCs) 4*10 per well 5 Cells (low-attachment 96-well plates, Corning 7007) were cultured in a medium containing Matrigel (100 mg / mL) and the induction medium A of Example 1; culture conditions: 37° C., 5% CO 2 ;

[0053] Day (1) Medium change: Each well was replaced with 200 μL of the induction medium B of Example 1; culture conditions: 37°C, 5% CO2;

[0054] Day (2) Medium change: Each well was replaced with 200 μL of the basal induction medium of Example 1; culture conditions: 37°C, 5% CO2;

[0055] Day (3)-(5) Medium change: Each well was replaced with 200 μL of the induction medium C of Example 1, and the medium was changed every day; culture conditions: 37°C, 5% CO2;

[0056] From Day (6) onwards, each well was replaced with 200 μL of the basal induction medium of Example 1, and the medium was changed every two days; culture conditions: 37°C, 5% CO2;

[0057] Day (15) achieved autonomous beating of the cardiac organoids, with expression of cardiac muscle cell genes such as NKX2-5, cTnT, and MLC2A.

[0058] Comparative Example 1: Cultivating cardiac organoids using other culture media

[0059] 1. Composition of contrast culture medium:

[0060] Comparative culture medium A: DMEM / F12 medium + CHIR99021 20 μM + Y-27632 20 μM;

[0061] Comparative medium B: DMEM / F12 medium + CHIR99021 10 μM;

[0062] 2. Cultivation process:

[0063] Day (0) Human pluripotent stem cells (hESCs, hIPSCs) 4*10 per well 5 Cells (low-attachment 96-well plates, Corning 7007) were cultured with Matrigel (100 mg / mL) and compared to Medium A; culture conditions: 37°C, 5% CO2;

[0064] Day (1) Medium change: 200 μL of control medium B per well; culture conditions: 37°C, 5% CO2;

[0065] Day (2) Medium change: 200 μL DMEM / F12 per well; culture conditions: 37°C, 5% CO2;

[0066] Day (3)-(5) Medium change: Each well was replaced with 200 μL DMEM / F12 + IWR-1 20 μM, TA-01, 15 μM, TA-02, 15 μM, and the medium was changed every day; culture conditions: 37°C, 5% CO2;

[0067] From Day (6) onwards, each well was replaced with 200 μL DMEM / F12, and the medium was changed every two days; culture conditions: 37° C., 5% CO 2 .

[0068] Comparative Example 2: Cultivating cardiac organoids using other culture media

[0069] 1. Composition of contrast culture medium:

[0070] Control medium a: RPMI 1640 medium + CHIR99021 20 μM + Y-27632 20 μM;

[0071] Control medium b: RPMI 1640 medium + CHIR99021 10 μM;

[0072] 2. Cultivation process:

[0073] Day (0) Human pluripotent stem cells (hESCs, hIPSCs) 4*10 per well 5 Cells (low-attachment 96-well plates, Corning 7007) were cultured with Matrigel (100 mg / mL) compared to medium a; culture conditions: 37°C, 5% CO2;

[0074] Day (1) Medium change: 200 μL of control medium b was added to each well; culture conditions: 37°C, 5% CO2;

[0075] Day (2) Medium change: 200 μL RPMI 1640 per well; culture conditions: 37°C, 5% CO2;

[0076] Day (3)-(5) Medium change: Each well was replaced with 200 μL RPMI 1640 + IWR-1 20 μM, TA-01, 15 μM, TA-02, 15 μM, and the medium was changed every day; culture conditions: 37°C, 5% CO2;

[0077] From Day (6) onwards, each well was replaced with 200 μL RPMI 1640, and the medium was changed every two days; culture conditions: 37° C., 5% CO 2 .

[0078] The beneficial effects of the present invention are demonstrated by experimental examples below.

[0079] Experimental Example 1: Immunofluorescence identification of cardiac muscle cells and cardiac organoids cultured according to the present invention, and identification of physiological electrical signals of cardiac organoids.

[0080] 1. Experimental methods

[0081] The organoids cultured in Example 2 were immunofluorescently stained for DAPI, MLC2A, Troponin T (cTnT), NKX2-5, MEF2C, and α-actinin, respectively, and observed using a Nikon Ti microscope platform. This platform was also used to analyze and record the spontaneous beats of the cardiac organoids (Figure 5). Electrophysiological signals from the cardiac organoids were also recorded and analyzed (Figure 5).

[0082] 2. Experimental results

[0083] The results are shown in Figures 2 to 5. Figure 2 shows that cardiac muscle cells differentiated using this kit in 2D culture express genes specific for cardiac precursor cells and mature cardiac cells, such as MLC2a, Troponin T, MEF2C, NKX2-5, and α-Actinin. Figure 3 shows immunofluorescence images of cardiac organoid sections differentiated using this kit in 3D culture. Similarly, expression of genes such as NKX2-5, MLC2A, and Troponin T (cTnT) is observed, confirming the presence of cardiac muscle cells in the organoids. Furthermore, the HE staining in Figure 4 reveals distinct cavities within the organoids, similar to those found in the human heart. Figure 5 records and analyzes the spontaneous beating rate and electrophysiological signals of the organoids, demonstrating their functionality.

[0084] Experimental Example 2: Development of Cultured Organoids

[0085] 1. Experimental methods

[0086] The organoids cultured in Example 2 and the organoids cultured in Comparative Examples 1 and 2 were observed using an optical microscope.

[0087] 2. Experimental results

[0088] The results are shown in Figure 3. It can be seen that the embryoid bodies obtained in Comparative Example 1 were too small and had no spontaneous beating, while the embryoid bodies obtained in Comparative Example 2 did not aggregate and had no spontaneous beating. However, the embryoid bodies obtained in the examples of the present invention developed normally and had spontaneous beating, demonstrating that the present invention successfully cultivated cardiac organoids.

[0089] In summary, the present invention provides a kit for constructing cardiac organoids from pluripotent stem cells, which can achieve the construction of autonomously beating cardiac organoids within 15 days. The constructed cardiac organoids are electrophysiologically stable and highly reproducible, and are suitable for applications including drug development, safety evaluation, and research on cardiac development processes.

Claims

1. A kit for constructing cardiac organoids from pluripotent stem cells, characterized in that: The invention comprises a basic induction medium component, wherein the basic induction medium component is composed of the following raw materials in parts by volume: DMEM medium 50 parts, MEM vitamin solution 0.05 parts, yeast powder ultrafiltrate 0.1 parts, vitamin E 5 parts, synthetic cholesterol 0.1 parts, yeast extract 3 parts, bovine serum albumin 5 parts, soybean hydrolyzate 5 parts; The vitamin E is a vitamin E solution with a concentration of 0.96 g / mL.

2. The kit according to claim 1, characterized in that It comprises an induction medium component A; the induction medium component A comprises the basic induction medium component, and further comprises additives with the following final concentrations added on the basis of the basic induction medium component: CHIR99021 15-25 μM, Y-27632 15-25 μM.

3. The kit according to claim 2, characterized in that The induction medium component A consists of the basic induction medium component and the additives; the final concentrations of the additives are: CHIR99021 20 μM, Y-27632 20 μM.

4. The kit according to claim 1, characterized in that The induction medium component B includes the basic induction medium component and an additive with the following final concentration added on the basis of the basic induction medium component: CHIR9902 15-15 μM.

5. The kit according to claim 4, characterized in that The induction medium component B consists of the basic induction medium component and the additive; the final concentration of the additive is: CHIR99021 10 μM.

6. The kit according to claim 1, characterized in that The induction medium component C includes the basic induction medium component and the additives with the following final concentrations added to the basic induction medium component: IWR-1 15-25 μM, TA-01 10-20 μM, and TA-02 10-20 μM.

7. The kit according to claim 6, characterized in that The induction medium component C is composed of the basic induction medium component and the additives; the final concentrations of the additives are: IWR-1 20 μM, TA-01 15 μM, TA-02 15 μM.

8. The kit according to any one of claims 1 to 7, characterized in that It includes a basic induction medium component, an induction medium A component, an induction medium B component and an induction medium C component; The basic induction medium is composed of the following raw materials: DMEM medium 50 mL, MEM vitamin solution 50 μL, yeast powder ultrafiltrate 100 μL, vitamin E 5 mL, synthetic cholesterol 100 μL, yeast extract 3 mL, bovine serum albumin 5 mL, soybean hydrolyzate 5 mL; The induction medium component A is composed of the following raw materials: the raw materials of the basic induction medium; and CHIR99021 with a final concentration of 20 μM and Y-27632 with a final concentration of 20 μM added to the raw material mixture of the basic induction medium; The induction medium component B is composed of the following raw materials: the raw materials of the basic induction medium; and CHIR99021 with a final concentration of 10 μM added to the raw material mixture of the basic induction medium; The induction medium component C is composed of the following raw materials: the raw materials of the basal induction medium; and IWR-1 with a final concentration of 20 μM, TA-01 with a final concentration of 15 μM, and TA-02 with a final concentration of 15 μM added to the raw material mixture of the basal induction medium.

9. A method for constructing cardiac organoids from pluripotent stem cells, characterized in that: The method comprises the step of inducing and culturing pluripotent stem cells using the kit according to any one of claims 1 to 8.

10. The method according to claim 9, characterized in that The steps include: (1) culturing human pluripotent stem cells in induction medium A for 1 day; (2) Change to induction medium B and culture for 1 day; (3) Change the basal induction medium and culture for 1 day; (4) Change to induction medium C for 3 days, and change to fresh induction medium C every day; (5) Continue culturing by replacing the basal induction medium with fresh basal induction medium every 2 days until the cardiac organoids experience autonomous beating and / or cardiac muscle cell gene expression.

Citation Information

Patent Citations

  • Method for constructing heart organoid based on human pluripotent stem cells

    CN114438021A

  • Heart organoid model and preparation method thereof

    CN114891731A

  • Method for culturing heart organoid by using self-assembled peptide and heart organoid

    CN114958728A

  • Vascularized heart organoid with cavity structure and preparation method of vascularized heart organoid

    CN115354017A

  • Culture medium, application thereof and method for culturing heart organoid

    CN115975907A